NeoGenomics, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
NeoGenomics, Inc. (NEO) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $8.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-07-28
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $8.22M, a 32.74% decline year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $9.64M, a 10.40% decline year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was $10.30M, a 21.66% increase year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-06-30 was $12.21M, a 38.16% increase year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $41.32M, a 23.65% increase from fiscal 2024.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $33.41M, a 35.64% increase from fiscal 2023.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $24.63M, a 0.16% decline from fiscal 2022.
- NeoGenomics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2022 was $24.67M, a 2245.25% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.22M 10-Q · filed 2026-07-28 | $17.85M derived: sum of 2 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | $9.64M 10-Q · filed 2026-07-28 | |||||
| 2025-12-31 | $41.32M 10-K · filed 2026-02-17 | |||||
| 2025-09-30 | $10.30M 10-Q · filed 2025-10-28 | $22.52M derived: sum of 2 quarters · filed 2026-07-28 | $33.27M derived: sum of 3 quarters · filed 2026-07-28 | |||
| 2025-06-30 | $12.21M 10-Q · filed 2026-07-28 | $22.97M derived: sum of 2 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $10.75M 10-Q · filed 2026-07-28 | |||||
| 2024-12-31 | $33.41M 10-K · filed 2026-02-17 | |||||
| 2024-09-30 | $8.47M 10-Q · filed 2025-10-28 | $17.31M derived: sum of 2 quarters · filed 2025-10-28 | $25.09M derived: sum of 3 quarters · filed 2025-10-28 | |||
| 2024-06-30 | $8.84M 10-Q · filed 2025-10-28 | $16.61M derived: sum of 2 quarters · filed 2025-10-28 | ||||
| 2024-03-31 | $7.77M 10-Q · filed 2025-10-28 | |||||
| 2023-12-31 | $24.63M 10-K · filed 2026-02-17 | |||||
| 2023-09-30 | $7.18M 10-Q · filed 2024-11-05 | $279.00K 10-Q · filed 2023-11-06 | $12.88M derived: sum of 2 quarters · filed 2024-11-05 | $17.64M derived: sum of 3 quarters · filed 2024-11-05 | ||
| 2023-06-30 | $5.71M 10-Q · filed 2024-11-05 | $255.00K 10-Q · filed 2023-08-08 | $10.46M derived: sum of 2 quarters · filed 2024-11-05 | |||
| 2023-03-31 | $4.76M 10-Q · filed 2024-11-05 | $275.00K 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $24.67M 10-K · filed 2025-02-18 | $1.04M 10-K · filed 2023-02-24 | ||||
| 2022-09-30 | $257.00K 10-Q · filed 2023-11-06 | $550.00K derived: sum of 2 quarters · filed 2023-11-06 | $799.00K derived: sum of 3 quarters · filed 2023-11-06 | |||
| 2022-06-30 | $293.00K 10-Q · filed 2023-11-06 | $542.00K derived: sum of 2 quarters · filed 2023-11-06 | ||||
| 2022-03-31 | $249.00K 10-Q · filed 2023-11-06 | |||||
| 2021-12-31 | $1.05M 10-K · filed 2023-02-24 | |||||
| 2021-09-30 | $236.00K 10-Q · filed 2022-11-08 | $534.00K derived: sum of 2 quarters · filed 2022-11-08 | $775.00K derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $298.00K 10-Q · filed 2022-11-08 | $539.00K derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $241.00K 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $875.00K 10-K · filed 2023-02-24 | |||||
| 2020-09-30 | $222.00K 10-Q · filed 2021-11-04 | $433.00K derived: sum of 2 quarters · filed 2021-11-04 | $627.00K derived: sum of 3 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $211.00K 10-Q · filed 2021-11-04 | $405.00K derived: sum of 2 quarters · filed 2021-11-04 | ||||
| 2020-03-31 | $194.00K 10-Q · filed 2021-11-04 | |||||
| 2019-12-31 | $609.00K 10-K · filed 2022-02-25 | |||||
| 2019-09-30 | $144.00K 10-Q · filed 2020-10-29 | $306.00K derived: sum of 2 quarters · filed 2020-10-29 | $425.00K derived: sum of 3 quarters · filed 2020-10-29 | |||
| 2019-06-30 | $162.00K 10-Q · filed 2020-10-29 | $281.00K derived: sum of 2 quarters · filed 2020-10-29 | ||||
| 2019-03-31 | $119.00K 10-Q · filed 2020-10-29 | |||||
| 2018-12-31 | $243.00K 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $56.00K 10-Q · filed 2019-11-13 | $112.00K derived: sum of 2 quarters · filed 2019-11-13 | $166.00K derived: sum of 3 quarters · filed 2019-11-13 | |||
| 2018-06-30 | $56.00K 10-Q · filed 2019-11-13 | $110.00K derived: sum of 2 quarters · filed 2019-11-13 | ||||
| 2018-03-31 | $54.00K 10-Q · filed 2019-11-13 | |||||
| 2017-12-31 | $96.00K 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |